TMCnet News
China Independent Clinical Laboratory Industry Report, 2017-2021 - Industry's Growth Rate Will Be Above 30% in the Next Five Years - Research and MarketsThe "China Independent Clinical Laboratory Industry Report, 2017-2021" report has been added to Research and Markets' offering. China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States and Japan. Furthermore, Chinese independent clinical laboratories can provide more than 2,000 test items, while the counterparts in the United States can offer over 4,000 test items. However, China's independent clinical laboratory industry is progressing rapidly, presenting the CAGR of 41.4% during 2010-2016, with the market size reaching RMB9.6 billion (an upsurge of 37.1% year on year) in 2016. Pushed by the promotion of hierarchical medical system and other favorable policies, the growth of the outsourcing demand from public and private hospitals under the pressure of cost control, the acceleration of population aging as well as the people's ever growing awareness of health, etc., the independent clinical laboratory market size in China will maintain growth rate of at least 30% in the next five years and reach RMB41.4 billion by 2021. As of the ed of 2016, there had been 468 independent clinical laboratories in China, an increase of 112 ones over the same period of last year. They were mainly distributed in the developed coastal areas, about 50% of which were located in Shanghai, Beijing, Guangdong, Zhejiang and Jiangsu. At present, major independent clinical laboratory companies in China include KingMed Diagnostics, ADICON, DIAN Diagnostics, DAAN Gene, Shanghai Labway Clinical Laboraory, MedicalSystem Biotechnology, Beijing Lepu Gene Technology and so forth. With cutting-edge advantages in the number of laboratories and inspection items which directly demonstrate the competitiveness of enterprises, KingMed Diagnostics, ADICON, DIAN Diagnostics and DAAN Gene held a combined market share of over 70% in 2016. Key Topics Covered: 1. Overview of Independent Clinical Laboratory 2. Overview of China Independent Clinical Laboratory Industry 3. Upstream and Downstream Sectors of China Independent Clinical Laboratory Industry 4. Key Players Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/research/5vbkv9/china_independent View source version on businesswire.com: http://www.businesswire.com/news/home/20170822005510/en/ |
